Nasdaq
$6.33▲ 0.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $263.5MShares out 41.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
24- 10.2Regular26.10.03 04:244Ownership#●●●
AGENUS INC
Timothy Wright, an executive at Agenus Inc., filed a Form 4 report on October 2, 2026, regarding changes in his beneficial ownership of company securities as of October 1, 2026.…more
$6.33+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2Regular26.10.03 04:214Ownership
AGENUS INC
Agenus Inc insider Thomas L. Harrison filed a Form 4 report regarding changes in beneficial ownership of securities as of October 1, 2026. This filing serves as a standard disclosure of insider equity movement, though specific transaction volumes or values were not disclosed in the summary.…more
$6.33+0.20%vs prev closeView filingShare - 9.16Regular26.09.17 03:414Ownership
AGENUS INC
Agenus Inc insider Marcucci Marco Tullio filed a Form 4 on September 16, 2026, regarding a change in beneficial ownership of securities effective August 5, 2026. This filing provides transparency regarding the insider's equity position in the company.…more
$6.33+0.20%vs prev closeView filingShare
23 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8Pre-market26.10.08 20:31#●●●#●●●
Agenus Receives First Global Marketing Authorization for Botvymo in Armenia…more
Agenus announced that the Armenian Ministry of Health has granted marketing authorization for the combination of Botvymo and Evamplix to treat adult patients with metastatic colorectal cancer. This marks the first global approval for these therapies, potentially serving as a milestone for the company's clinical pipeline.…more
$6.33+0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.5Overnight26.10.05 15:57
●●●●●●●● ●●●●● ●●●●●●
Agenus announced that 48% of evaluable recurrent ovarian cancer patients in its study achieved an estimated three-year survival rate. While the results demonstrate durable benefits in a difficult-to-treat population, further clinical validation remains necessary.…more
$6.33+0.20%vs prev closeShareBenzinga - 10.2Pre-market26.10.02 22:03
●●●●●●●● ●●●●● ●●●●●●
Agenus announced that research on its botensilimab and balstilimab combination therapy will be presented at the SITC 2026 annual meeting. The presentations will cover clinical data from refractory colorectal cancer patients and preclinical results involving iNKT cell therapy.…more
$6.33+0.20%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report